Esch Sur Alzette

Researchers are evaluating the medical benefit of spa therapy on skin and soft tissue fibrosis that occurs as a late reaction at least 6 months after radiotherapy for breast cancer or Upper Aerodigestive Tract UADT cancer. This randomized, controlled, multicenter trial aims to assess improvements in quality of life related to dermatological sequelae of fibrosis. The study focuses on patients with severe late reactions and compares immediate versus delayed spa treatment. The intervention being studied is a dermatologically oriented thermal cure that includes sedative and muscle-relaxing baths, decongestant sprays, and high-pressure thread-like showers using thermal water. Educational workshops on relaxation, sophrology, and hygiene are also part of the therapy. Participants are randomly assigned to receive spa treatment either immediately within 6 weeks of inclusion or after a 6-month delay, allowing comparison of outcomes between early and late treatment groups. Participants will be involved for at least 6 months, during which they will self-assess their dermatological quality of life using the DLQI score and undergo evaluations of generic and cancer-specific quality of life. Additional assessments include self-reported sequelae, radiological examinations of lesions, thickness, and volume, as well as monitoring of treatment and medical consultations. Adverse events and long-term quality of life benefits up to 12 months will be recorded to understand the therapys impact and safety.